Wegovy Week 5: What to Expect at the 0.5mg Dose

The decision most people face in week 5: is this normal, or is something wrong?

The jump from 0.25mg to 0.5mg is the first time many people feel Wegovy actually doing something. Satiety signals arrive earlier in a meal. Portions that felt routine now feel like too much. For some, nausea that had largely settled in weeks 3 and 4 returns briefly, less intense than week 1, but noticeable.

This is expected. The 0.25mg dose exists primarily to let your digestive system adapt to a GLP-1 receptor agonist; it was never designed to be the dose that drives sustained weight loss. At 0.5mg the medicine is beginning to work in earnest.

The decision most people find themselves weighing is whether their symptoms are a normal response to the new dose or a signal to pause. Broadly: nausea that is manageable and easing over several days is typical. Nausea that is preventing you from keeping food or fluids down, or stomach pain that is severe and persistent, warrants a call to your prescriber rather than waiting it out. When in doubt, contact your clinical team, that is exactly what the aftercare number is for.

It is also worth knowing that the overall arc of Wegovy treatment is gradual by design. Most of the weight-loss results in clinical trials accumulated over 68 weeks, not five.

What hunger and appetite typically feel like by this point

One of the clearest descriptions our prescribers hear from people in week 5 is that food has simply become less interesting. Not absent from their thoughts entirely, but quieter. The pull toward snacking between meals fades for many people. Portion sizes shrink without what had previously felt like willpower.

This is semaglutide's main mechanism working: slowing gastric emptying and signalling fullness through GLP-1 pathways in the brain. At 0.5mg that signal is stronger than at the starter dose, though it is still well below the 2.4mg maintenance dose that produced the results described in the STEP 1 trial, published in the New England Journal of Medicine, where participants lost around 15% of body weight on average over 68 weeks.

If appetite feels broadly unchanged compared with week 4, that does not mean the medicine is not working. Individual responses to each dose step vary, and the effect continues to build as semaglutide reaches steady state in the body, a process that takes several weeks at each new dose level.

One small practical note: if you keep your pen in the fridge door, check it is actually at the back where temperature is most stable, not in a shelf exposed to warm air every time the door opens.

Side effects at week 5: what tends to ease and what sometimes worsens

For most people, the pattern at week 5 mirrors week 1 on a smaller scale. The digestive system has adapted somewhat to GLP-1 activity, so the 0.5mg increase usually produces a milder reaction than the original 0.25mg dose did. Nausea is the most common complaint; diarrhoea and constipation each affect a meaningful proportion of people, often alternating. Fatigue and mild headache are also reported in the first few days after a dose change.

Eating smaller meals, keeping protein intake up, staying well hydrated, and avoiding fatty or heavily spiced food in the first week at the new dose all help. These are not rules, they are practical adjustments that many people find reduce discomfort without needing any medication change.

The side effects worth acting on promptly are different in character: severe, unrelenting upper abdominal pain that radiates toward the back, with or without vomiting, should be assessed urgently. Pancreatitis is a rare but serious side effect associated with GLP-1 medicines, and the MHRA's safety guidance is clear that this symptom pattern warrants immediate medical attention rather than a wait-and-see approach. Any suspected side effect can also be reported via the Yellow Card scheme.

Weighing your options if week 5 is harder than expected

Some people find the step to 0.5mg genuinely difficult. That is not a reason to stop, but it may be a reason to have an honest conversation with your prescriber about pacing. Staying at a dose longer than the standard four-week window is sometimes the right call. Your prescriber makes that assessment; it is not something to manage unilaterally.

If you are considering whether to continue at all, it is worth reading about how long Wegovy typically takes to produce visible results, most people are still in the early adjustment phase at week 5, and stopping here means leaving most of the potential benefit unreached.

For anyone who started on Wegovy through a different provider and has questions about how week 5 compares with typical experiences, or is wondering what the journey ahead looks like, our frequently asked questions cover a lot of the practical detail. If you have not yet started treatment and want to understand whether Wegovy suits your situation, a free consultation with our prescribers is the place to begin, no obligation, and reviewed the same day by a real clinician.

For context on how week 5 sits within the wider picture, our page covering Wegovy in full explains the entire titration schedule and what clinical supervision looks like at each stage. You might also find it useful to look back at what week 1 typically involved and compare notes with where you are now. If you want a closer look at how the early weeks unfold, our guides to what to expect in your second week of Wegovy and how week 2 of Wegovy typically feels for most people are worth reading alongside this page.